biotech / news / / The Manila Times
Sanofi’s lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP.
Lunsekimig met primary and key secondary endpoints in phase 2 asthma and CRSwNP studies.
KEY POINTS
- AIRCULES study showed lunsekimig reduced asthma exacerbations and improved lung function regardless of biomarker status.
- DUET study confirmed lunsekimig improved nasal polyp score and nasal congestion in CRSwNP patients.
- VELVET study found lunsekimig did not meet its primary endpoint in atopic dermatitis.
- Lunsekimig was generally well tolerated, with adverse event rates similar to placebo across studies.
COMPANIES
Summarized by Newsio from The Manila Times. How we summarize →